Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children

Zynerba Pharmaceuticals Inc ZYNE presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment period.
Zygel is cannabidiol formulated in a transdermal gel.
The data were presented at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021.
The open-label Phase 2 study demonstrated over 35% improvement in the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale at week 14. Patients were allowed to continue treatment for an additional 24 weeks.
In the 18 patients who completed treatment through additional 24 weeks, Zygel improved ABC-C subscale scores (51% to 61% across domains).
Improvements in the Parent-Rated Anxiety Scale-ASD score (42%), Autism Parenting Stress Index (40%), and the Autism Impact Measure (19% to 36% across domains) were observed, relative to baseline.
Zygel was generally well-tolerated, and the safety profile was consistent with data from previous Zygel clinical trials.
Price Action: ZYNE stock is up 4.63% at $4.52 during the market session on the last check Thursday.